Molecular imaging of apoptosis: From micro to macro

Theranostics

Volumn 5, Issue 6, 2015, Pages 559-582

  Zeng, Wenbin ^a   Wang, Xiaobo ^a   Xu, Pengfei ^a   Liu, Gang ^b   Eden, Henry S ^c   Chen, Xiaoyuan ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING   (United States)

Author keywords

Apoptosis; Clinical translation; Macroscopic imaging probes; Microscopic imaging assays

Indexed keywords

2,2',2'' (1,4,7 TRIAZACYCLONONANE 1,4,7 TRIYL)TRIACETIC ACID; 4 (5 DIMETHYLAMINO NAPHTHALENE 1 SULFONAMIDO) 3 (4 IODOPHENYL)BUTANOIC ACID; 4,5 BIS(THIOACETAMIDO)PENTANOYL ANNEXIN 5 TC 99M; CASPASE; FLUORESCENT DYE; GADOLINIUM CHELATE; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE BIS(STEARYLAMIDE); GADOTERIC ACID; HYDRAZIONONICOTINAMIDE ANNEXIN 5 TC 99M; HYDRAZIONONICOTINAMIDE LACTADHERIN TC 99M; LANCOVUTIDE; LIPOCORTIN 5; LIPOCORTIN 5 F 18; N SUCCINIMIDYL 4 FLUOROBENZOATE F 18; N [4 [(4 FLUOROBENZYLIDENE)AMINOOXY]BUTYL]MALEIMIDE F 18; NANOPARTICLE; PENTETIC ACID; RADIOPHARMACEUTICAL AGENT; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; TETRAXETAN; UNCLASSIFIED DRUG; APOPTOSIS REGULATORY PROTEIN;

APOPTOSIS; BIOLUMINESCENCE; BRAIN ISCHEMIA; BRAIN METASTASIS; CASPASE ASSAY; DRUG CONJUGATION; ECHOGRAPHY; FLUORESCENCE ANALYSIS; FLUORESCENCE IMAGING; HUMAN; ISOTOPE LABELING; MICELLE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOLECULAR IMAGING; MOLECULAR PROBE; NON SMALL CELL LUNG CANCER; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SCINTISCANNING; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUNEL ASSAY; UTERINE TUBE CARCINOMA; ANIMAL; CHEMISTRY; FLUORESCENCE MICROSCOPY; METABOLISM; PROCEDURES;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; FLUORESCENT DYES; HUMANS; MICROSCOPY, FLUORESCENCE; MOLECULAR IMAGING; RADIOPHARMACEUTICALS;

EID: 84930661848     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.11548     Document Type: Review

References (223)

1. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972; 26: 239-57.
2. Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science. 2004; 305: 626-9.
3. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008; 132: 27-42.
4. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444: 756-60.
5. Starkey JR, Rebane AK, Drobizhev MA, Meng F, Gong A, Elliott A, et al. New two-photon activated photodynamic therapy sensitizers induce xenograft tumor regressions after near-IR laser treatment through the body of the host mouse. Clin Cancer Res. 2008; 14: 6564-73.
6. Zhang L, Ren X, Alt E, Bai X, Huang S, Xu Z, et al. Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature. 2010; 464:1058-61.
7. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998; 281: 1305-8.
8. Hengartner MO. The biochemistry of apoptosis. Nature. 2000; 407: 770-6.
9. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007; 8: 519-29.
10. Tabas I, Ron D. Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol. 2011; 13: 184-90.
11. Leist M, Jäättelä M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol. 2001; 2: 589-98.
12. Schlegel RA, Williamson P. Phosphatidylserine, a death knell. Cell Death Differ. 2001; 8: 551-63.
13. Han J, Zhong C, Zhang D. Programmed necrosis: backup to and competitor with apoptosis in the immune system. Nat Immunol. 2011; 12: 1143-9.
14. Liu P, Xu B, Shen W, Zhu H, Wu W, Fu Y, et al. Dysregulation of TNFα-induced necroptotic signaling in chronic lymphocytic leukemia: suppression of CYLD gene by LEF1. Leukemia. 2012; 26: 1293-300.
15. Weissleder R. Molecular imaging: exploring the next frontier. Radiology. 1999; 212: 609-14.
16. Gerke V, Moss SE. Annexins: from structure to function. Physiol Rev. 2002; 82:331-71.
17. Oling F, Bergsma-Schutter W, Brisson A. Trimers, dimers of trimers, and trimers of trimers are common building blocks of annexin a5 two-dimensional crystals. J Struct Biol. 2001; 133: 55-63.
18. van den Eijnde SM, Luijsterburg AJ, Boshart L, De Zeeuw CI, van Dierendonck JH, Reutelingsperger CP, et al. In situ detection of apoptosis during embryogenesis with annexin V: from whole mount to ultrastructure. Cytometry. 1997; 29: 313-20.
19. van den Eijnde SM, Boshart L, Reutelingsperger CP, Zeeuw CI, Vermeij-Keers C. Phosphatidylserine plasma membrane asymmetry in vivo: a pancellular phenomenon which alters during apoptosis. Cell Death Differ. 1997; 4: 311-6.
20. Kim YE, Chen J, Chan JR, Langen R. Engineering a polarity-sensitive biosensor for time-lapse imaging of apoptotic processes and degeneration. Nat Methods. 2010; 7: 67-73.
21. Kim YE, Chen J, Langen R, Chan JR. Monitoring apoptosis and neuronal degeneration by real-time detection of phosphatidylserine externalization using a polarity-sensitive indicator of viability and apoptosis. Nat Protoc. 2010; 5: 1396-405.
22. Krajewska M, You Z, Rong J, Kress C, Huang X, Yang J, et al. Neuronal deletion of caspase 8 protects against brain injury in mouse models of controlled cortical impact and kainic acid-induced excitotoxicity. PLoS One. 2011; 6:24341.
23. Bleackley RC, Heibein JA. Enzymatic control of apoptosis. Nat Prod Rep. 2001; 18: 431-40.
24. Cen H, Mao F, Aronchik I, Fuentes RJ, Firestone GL. DEVD-NucView488: a novel class of enzyme substrates for real-time detection of caspase-3 activity in live cells. FASEB J. 2008; 22: 2243-52.
25. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998; 281: 1309-12.
26. Cossarizza A, Baccarani-Contri M, Kalashnikova G, Franceschi C. A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1). Biochem Biophys Res Commun. 1993; 197: 40-5.
27. Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett. 1997; 411: 77-82.
28. Smiley ST, Reers M, Mottola-Hartshorn C, Lin M, Chen A, Smith TW, et al. Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A. 1991; 88: 3671-5.
29. Bouchier-Hayes L, Muñoz-Pinedo C, Connell S, Green DR. Measuring apoptosis at the single cell level. Methods. 2008; 44: 222-8.
30. Bortner CD, Oldenburg NB, Cidlowski JA. The role of DNA fragmentation in apoptosis. Trends Cell Biol. 1995; 5: 21-6.
31. Collins JA, Schandi CA, Young KK, Vesely J, Willingham MC. Major DNA fragmentation is a late event in apoptosis. J Histochem Cytochem. 1997; 45:923-34.
32. Gorczyca W, Gong J, Darzynkiewicz Z. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res. 1993; 53: 1945-51.
33. Negoescu A, Guillermet C, Lorimier P, Brambilla E, Labat-Moleur F. Importance of DNA fragmentation in apoptosis with regard to TUNEL specificity. Biomed Pharmacother. 1998; 52: 252-8.
34. Meldal M, Tornøe CW. Cu-catalyzed azide-alkyne cycloaddition. Chem Rev. 2008; 108: 2952-3015.
35. Salic A, Mitchison TJ. A chemical method for fast and sensitive detection of DNA synthesis in vivo. Proc Natl Acad Sci U S A. 2008; 105: 2415-20.
36. Smith G, Nguyen QD, Aboagye EO. Translational imaging of apoptosis. Anticancer Agents Med Chem. 2009; 9: 958-67.
37. Damianovich M, Ziv I, Heyman SN, Rosen S, Shina A, Kidron D, et al. Apo-Sense: a novel technology for functional molecular imaging of cell death in models of acute renal tubular necrosis. Eur J Nucl Med Mol Imaging. 2006; 33:281-91.
38. Watanabe M, Hitomi M, van der Wee K, Rothenberg F, Fisher SA, Zucker R, et al. The pros and cons of apoptosis assays for use in the study of cells, tissues, and organs. Microsc Microanal. 2002; 8: 375-91.
39. Hakumäki JM, Liimatainen T. Molecular imaging of apoptosis in cancer. Eur J Radiol. 2005; 56: 143-53.
40. Sugiura G, Kühn H, Sauter M, Haberkorn U, Mier W. Radiolabeling strategies for tumor-targeting proteinaceous drugs. Molecules. 2014; 19: 2135-65.
41. Lahorte CM, Vanderheyden JL, Steinmetz N, van de Wiele C, Dierckx RA, Slegers G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging. 2004; 31: 887-919.
42. Lee S, Xie J, Chen X. Peptides and peptide hormones for molecular imaging and disease diagnosis. Chem Rev. 2010; 110: 3087-111.
43. Blankenberg FG, Katsikis PD, Tait JF, Davis RE, Naumovski L, Ohtsuki K, et al. In vivo detection and imaging of phosphatidylserine expression during programmed cell death. Proc Natl Acad Sci U S A. 1998; 95: 6349-54.
44. Stratton JR, Dewhurst TA, Kasina S, Reno JM, Cerqueira MD, Baskin DG, et al. Selective uptake of radiolabeled annexin V on acute porcine left atrial thrombi. Circulation. 1995; 92: 3113-21.
45. Fonge H, de Saint Hubert M, Vunckx K, Rattat D, Nuyts J, Bormans G, et al. Preliminary in vivo evaluation of a novel 99mTc-labeled HYNIC-cys-annexin A5 as an apoptosis imaging agent. Bioorg Med Chem Lett. 2008; 18: 3794-8.
46. Vanderheyden JL, Liu G, He J, Patel B, Tait JF, Hnatowich DJ. Evaluation of 99mTc-MAG3-annexin A5: influence of the chelate on in vitro and in vivo properties in mice. Nucl Med Biol. 2006; 33: 135-44.
47. Yang DJ, Azhdarinia A, Wu P, Yu DF, Tansey W, Kalimi SK, et al. In vivo and in vitro measurement of apoptosis in breast cancer cells using 99mTc-EC-annexin V. Cancer Biother Radiopharm. 2001; 16: 73-83.
48. Tait JF, Brown DS, Gibson DF, Blankenberg FG, Strauss HW. Development and characterization of annexin V mutants with endogenous chelation sites for 99mTc. Bioconjug Chem. 2000; 11: 918-25.
49. Tait JF, Smith C, Gibson DF. Development of annexin V mutants suitable for labeling with Tc(I)-carbonyl complex. Bioconjug Chem. 2002; 13: 1119-23.
50. Wen X, Wu QP, Ke S, Wallace S, Charnsangavej C, Huang P, et al. Improved radiolabeling of PEGylated protein: PEGylated annexin V for noninvasive imaging of tumor apoptosis. Cancer Biother Radiopharm. 2003; 18: 819-27.
51. Ke S, Wen X, Wu QP, Wallace S, Charnsangavej C, Stachowiak AM, et al. Imaging taxane-induced tumor apoptosis using PEGylated, 111In-labeled annexin V. J Nucl Med 2004; 45: 108-15.
52. Smith-Jones PM, Afroze A, Zanzonico P, Tait J, Larson SM, Strauss HW. 68Ga labelling of annexin-V: comparison to 99mTc-annexin-V and 67Ga-Annexin. J Nucl Med. 2003; 44(Suppl 1): S49-S50.
53. Wängler C, Wängler B, Lehner S, Elsner A, Todica A, Bartenstein P, et al. A universally applicable 68Ga-labeling technique for proteins. J Nucl Med. 2011; 52: 586-91.
54. Li X, Link JM, Stekhova S, Yagle KJ, Smith C, Krohn KA, et al. Site-specific labeling of annexin V with F-18 for apoptosis imaging. Bioconjug Chem. 2008; 19: 1684-8.
55. Dekker B, Keen H, Lyons S, Disley L, Hastings D, Reader A, et al. MBP-annexin A5 radiolabelled directly with iodine-124 can be used to image apoptosis in vivo using PET. Nucl Med Biol. 2005; 32: 241-52.
56. Cauchon N, Langlois R, Rousseau JA, Tessier G, Cadorette J, Lecomte R, et al. PET imaging of apoptosis with 64Cu-labeled streptavidin following pretargeting of phosphatidylserine with biotinylated annexin-V. Eur J Nucl Med Mol Imaging. 2007; 34: 247-58.
57. Cheng Q, Lu L, Grafström J, Olofsson MH, Thorell JO, Samén E, et al. Combining [11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenografts. PLoS One. 2012; 7: 42151.
58. Cheng Q, Lu L, Grafström J, Olofsson MH, Thorell JO, Samén E, et al. Site-specifically 11C-labeled Sel-tagged annexin A5 and a size-matched control for dynamic in vivo PET imaging of protein distribution in tissues prior to and after induced cell death. Biochim Biophys Acta. 2013; 1830: 2562-73.
59. Wang F, Fang W, Zhang MR, Zhao M, Liu B, Wang Z, et al. Evaluation of chemotherapy response in VX2 rabbit lung cancer with 18F-labeled C2A domain of synaptotagmin I. J Nucl Med. 2011; 52: 592-9.
60. Zhao M, Zhu X, Ji S, Zhou J, Ozker KS, Fang W, et al. 99mTc-labeled C2A domain of synaptotagmin I as a target-specific molecular probe for noninvasive imaging of acute myocardial infarction. J Nucl Med. 2006; 47: 1367-74.
61. Waehrens LN, Rasmussen JT, Heegaard CW, Falborg L. Preparation and in vitro evaluation of 99mTc-labelled bovine lactadherin as a novel radioligand for apoptosis detection. J Label Compd Radiopharm. 2007; 50: 211-17.
62. Lahorte CM, Vanderheyden JL, Steinmetz N, van de Wiele C, Dierckx RA, Slegers G. Apoptosis-detecting radioligands: current state of the art and future perspectives. Eur J Nucl Med Mol Imaging. 2004; 31: 887-919.
63. Boersma HH, Kietselaer BL, Stolk LM, Bennaghmouch A, Hofstra L, Narula J, et al. Past, present, and future of annexin A5: from protein discovery to clinical applications. J Nucl Med. 2005; 46: 2035-50.
64. Vangestel C, Peeters M, Mees G, Oltenfreiter R, Boersma HH, Elsinga PH, et al. In vivo imaging of apoptosis in oncology: an update. Mol Imaging. 2011; 10:340-58.
65. Kemerink GJ, Boersma HH, Thimister PW, Hofstra L, Liem IH, Pakbiers MT, et al. Biodistribution and dosimetry of 99mTc-BTAP-annexin-V in humans. Eur J Nucl Med. 2001; 28: 1373-8.
66. Narula J, Acio ER, Narula N, Samuels LE, Fyfe B, Wood D, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 2001; 7: 1347-52.
67. Hofstra L, Dumont EA, Thimister PW, Heidendal GA, DeBruine AP, Elenbaas TW, et al. In vivo detection of apoptosis in an intracardiac tumor. J Am Med Assoc. 2001; 285: 1841-2.
68. Kown MH, Strauss HW, Blankenberg FG, Berry GJ, Stafford-Cecil S, Tait JF, et al. In vivo imaging of acute cardiac rejection in human patients using 99mtechnetium labeled annexin V. Am J Transplant. 2001; 1: 270-7.
69. Abrams MJ, Juweid M, tenKate CI, Schwartz DA, Hauser MM, Gaul FE, et al. Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. J Nucl Med. 1990; 31: 2022-8.
70. Kown MH, van der Steenhoven TJ, Jahncke CL, Mari C, Lijkwan MA, Koransky ML, et al. Zinc chloride-mediated reduction of apoptosis as an adjunct immunosuppressive modality in cardiac transplantation. J Heart Lung Transplant. 2002; 21: 360-5.
71. Belhocine T, Steinmetz N, Hustinx R, Bartsch P, Jerusalem G, Seidel L, et al. Increased uptake of the apoptosis-imaging agent 99mTc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res. 2002; 8: 2766-74.
72. Kemerink GJ, Liu X, Kieffer D, Ceyssens S, Mortelmans L, Verbruggen AM, et al. Safety, biodistribution, and dosimetry of 99mTc-HYNIC-annexin V, a novel human recombinant annexin V for human application. J Nucl Med. 2003; 44:947-52.
73. Hoebers FJ, Kartachova M, de Bois J, van den Brekel MW, van Tinteren H, van Herk M, et al. 99mTc Hynic-rh-Annexin V scintigraphy for in vivo imaging of apoptosis in patients with head and neck cancer treated with chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2008; 35: 509-18.
74. Rottey S, van den Bossche B, Slegers G, Van Belle S, van de Wiele C. Influence of chemotherapy on the biodistribution of [99mTc]hydrazinonicotinamide annexin V in cancer patients. Q J Nucl Med Mol Imaging. 2009; 53: 127-32.
75. Kartachova M, van Zandwijk N, Burgers S, van Tinteren H, Verheij M, Valdés Olmos RA. Prognostic significance of 99mTc Hynic-rh-annexin V scintigraphy during platinum-based chemotherapy in advanced lung cancer. J Clin Oncol. 2007; 25: 2534-9.
76. Kartachova MS, Valdés Olmos RA, Haas RL, Hoebers FJ, Herk M, Verheij M. 99mTc-HYNIC-rh-annexin-V scintigraphy: visual and quantitative evaluation of early treatment-induced apoptosis to predict treatment outcome. Nucl Med Commun. 2008; 29: 39-44.
77. Lu C, Jiang Q, Hu M, Tan C, Ji Y, Yu H, et al. Preliminary biological evaluation of novel 99mTc-Cys-annexin A5 as a apoptosis imaging agent. Molecules. 2013; 18: 6908-18.
78. Benali K, Louedec L, Azzouna RB, Merceron O, Nassar P, Al Shoukr F, et al. Preclinical validation of 99mTc-annexin A5-128 in experimental autoimmune myocarditis and infective endocarditis: comparison with 99mTc-HYNIC-annexin A5. Mol Imaging. 2014; 13: 1-10.
79. Mukherjee A, Kothari K, Tóth G, Szemenyei E, Sarma HD, Környei J, et al. 99mTc-labeled annexin V fragments: a potential SPECT radiopharmaceutical for imaging cell death. Nucl Med Biol. 2006; 33: 635-43.
80. Tait JF, Smith C, Levashova Z, Patel B, Blankenberg FG, Vanderheyden JL. Improved detection of cell death in vivo with annexin V radiolabeled by site-specific methods. J Nucl Med. 2006; 47: 1546-53.
81. Yagle KJ, Eary JF, Tait JF, Grierson JR, Link JM, Lewellen B, et al. Evaluation of 18F-annexin V as a PET imaging agent in an animal model of apoptosis. J Nucl Med. 2005; 46: 658-66.
82. Murakami Y, Takamatsu H, Taki J, Tatsumi M, Noda A, Ichise R, et al. 18F-labelled annexin V: a PET tracer for apoptosis imaging. Eur J Nucl Med Mol Imaging. 2004; 31: 469-74.
83. Hu S, Kiesewetter DO, Zhu L, Guo N, Gao H, Liu G, et al. Longitudinal PET imaging of doxorubicin-induced cell death with 18F-Annexin V. Mol Imaging Biol. 2012; 14: 762-70.
84. Falborg L, Waehrens LN, Alsner J, Bluhme H, Frøkiaer J, Heegaard CW, et al. Biodistribution of 99mTc-HYNIC-lactadherin in mice-a potential tracer for visualizing apoptosis in vivo. Scand J Clin Lab Invest. 2012; 70: 209-16.
85. Poulsen RH, Rasmussen JT, Ejlersen JA, Flø C, Falborg L, Heegaard CW, et al. Pharmacokinetics of the phosphatidylserine tracers 99mTc-lactadherin and 99mTc-annexin V in pigs. EJNMMI Res. 2013; 3: 15.
86. Xiong C, Brewer K, Song S, Zhang R, Lu W, Wen X, et al. Peptide-based imaging agents targeting phosphatidylserine for the detection of apoptosis. J Med Chem. 2011; 54: 1825-35.
87. Song S, Xiong C, Lu W, Ku G, Huang G, Li C. Apoptosis imaging probe predicts early chemotherapy response in preclinical models: A comparative study with 18F-FDG PET. J Nucl Med. 2013; 54: 104-10.
88. Marconescu A, Thorpe PE. Coincident exposure of phosphatidylethanolamine and anionic phospholipids on the surface of irradiated cells. Biochim Biophys Acta. 2008; 1778: 2217-24.
89. Zhao M, Li Z, Bugenhagen S. 99mTc-labeled duramycin as a novel phosphatidylethanolamine-binding molecular probe. J Nucl Med. 2008; 49: 1345-52.
90. Johnson SE, Li Z, Liu Y, Moulder JE, Zhao M. Whole-body imaging of high-dose ionizing irradiation-induced tissue injuries using 99mTc-duramycin. J Nucl Med. 2013; 54: 1397-403.
91. Zhang Y, Stevenson GD, Barber C, Furenlid LR, Barrett HH, Woolfenden JM, et al. Imaging of rat cerebral ischemia-reperfusion injury using 99mTc-labeled duramycin. Nucl Med Biol. 2013; 40: 80-8.
92. Zhao M, Li Z. A single-step kit formulation for the 99mTc-labeling of HYNIC-Duramycin. Nucl Med Biol. 2012; 39: 1006-11.
93. Ohsawa S, Hamada S, Yoshida H, Miura M. Caspase-mediated changes in histone H1 in early apoptosis: prolonged caspase activation in developing olfactory sensory neurons. Cell Death Differ. 2008; 15: 1429-39.
94. Wang K, Purushotham S, Lee JY, Na MH, Park H, Oh SJ, et al. In vivo imaging of tumor apoptosis using histone H1-targeting peptide. J Control Release. 2010; 148: 283-91.
95. Haberkorn U, Kinscherf R, Krammer PH, Mier M, Eisenhut M. Investigation of a potential scintigraphic marker of apoptosis: radioiodinated Z-Val-Ala-DL-Asp(O-methyl)-fluoromethyl ketone. Nucl Med Biol. 2001; 28:793-8.
96. Bauer C, Bauder-Wuest U, Mier W, Haberkorn U, Eisenhut M. 131I-labeled peptides as caspase substrates for apoptosis imaging. J Nucl Med. 2005; 46:1066-74.
97. Su H, Chen G, Gangadharmath U, Gomez LF, Liang Q, Mu F, et al. Evaluation of [18F]-CP18 as a PET imaging tracer for apoptosis. Mol Imaging Biol. 2013; 15:739-47.
98. Xia CF, Chen G, Gangadharmath U, Gomez LF, Liang Q, Mu F, et al. In vitro and in vivo evaluation of the caspase-3 substrate-based radiotracer [18F]-CP18 for PET imaging of apoptosis in tumors. Mol Imaging Biol. 2013; 15: 748-57.
99. Doss M, Kolb HC, Walsh JC, Mocharla V, Fan H, Chaudhary A, et al. Biodistribution and radiation dosimetry of 18F-CP-18, a potential apoptosis imaging agent, as determined from PET/CT scans in healthy volunteers. J Nucl Med. 2013; 54: 2087-92.
100. Niu G, Chen X. Molecular imaging with activatable reporter systems. Theranostics. 2012; 2: 413-23.
101. Wang F, Wang Z, Hida N, Kiesewetter DO, Ma Y, Yang K, et al. A cyclic HSV1-TK reporter for real-time PET imaging of apoptosis. Proc Natl Acad Sci U S A. 2014; 111: 5165-70.
102. Koulov AV, Stucker KA, Lakshmi C, Robinson JP, Smith BD. Detection of apoptotic cells using a synthetic fluorescent sensor for membrane surfaces that contain phosphatidylserine. Cell Death Differ. 2003; 10: 1357-9.
103. Hanshaw RG, Smith BD. New reagents for phosphatidylserine recognition and detection of apoptosis. Bioorg Med Chem. 2005; 13: 5035-42.
104. Smith BA, Xiao S, Wolter W, Wheeler J, Suckow MA, Smith BD. In vivo targeting of cell death using a synthetic fluorescent molecular probe. Apoptosis. 2011; 16: 722-31.
105. Smith BA, Xie BW, van Beek ER, Que I, Blankevoort V, Xiao S, et al. Multicolor fluorescence imaging of traumatic brain injury in a cryolesion mouse model. ACS Chem Neurosci. 2012; 3: 530-7.
106. Wyffels L, Gray BD, Barber C, Moore SK, Woolfenden JM, Pak KY, et al. Synthesis and preliminary evaluation of radiolabeled bis(zinc(II)-dipicolylamine) coordination complexes as cell death imaging agents. Bioorg Med Chem. 2011; 19: 3425-33.
107. Oltmanns D, Zitzmann-Kolbe S, Mueller A, Bauder-Wuest U, Schaefer M, Eder M, et al. Zn(II)-bis(cyclen) complexes and the imaging of apoptosis/necrosis. Bioconjug Chem. 2011; 22: 2611-24.
108. Liu X, Cheng D, Gray BD, Wang Y, Akalin A, Rusckowski M, et al. Radiolabeled Zn-DPA as a potential infection imaging agent. Nucl. Med. Biol. 2012; 39: 709-14.
109. Aloya R, Shirvan A, Grimberg H, Reshef A, Levin G, Kidron D, et al. Molecular imaging of cell death in vivo by a novel small molecule probe. Apoptosis. 2006; 11: 2089-101.
110. Reshef A, Shirvan A, Grimberg H, Levin G, Cohen A, Mayk A, et al. Novel molecular imaging of cell death in experimental cerebral stroke. Brain Res. 2007; 1144: 156-64.
111. Cohen A, Ziv I, Aloya T, Levin G, Kidron D, Grimberg H, et al. Monitoring of chemotherapy-induced cell death in melanoma tumors by N,N'-Didansyl-L-cystine. Tech Cancer Res T. 2007; 6: 221-34.
112. Grimberg H, Levin G, Shirvan A, Cohen A, Reshef A, Ziv I. Monitoring of tumor response to chemotherapy in vivo by a novel small-molecule detector of apoptosis. Apoptosis 2009; 14: 257-67.
113. Reshef A, Shirvan A, Waterhouse RN, Grimberg H, Levin G, Cohen A, et al. Molecular imaging of neurovascular cell death in experimental cerebral stroke by PET. J Nucl Med. 2008; 49: 1520-8.
114. Höglund J, Shirvan A, Antoni G, Gustavsson SÅ, Långström B, Ringheim A, et al. 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med. 2011; 52: 720-5.
115. Shirvan A, Reshef A, Allen A, Fenig E, Stenmetz A, Groshar D, et al. Apoptosis imaging with PET-18F-ML-10 for early assessment of response of brain metastases to radiotherapy. J Nucl Med. 2009; 50(Suppl 2): S453.
116. Allen AM, Ben-Ami M, Reshef A, Steinmetz A, Kundel Y, Inbar E, et al. Assessment of response of brain metastases to radiotherapy by PET imaging of apoptosis with 18F-ML-10. Eur J Nucl Med Mol Imaging. 2012; 39: 1400-8.
117. Bauwens M, de Saint-Hubert M, Cleynhens J, Brams L, Devos E, Mottaghy FM, et al. Radioiodinated phenylalkyl malonic acid derivatives as pH-sensitive SPECT tracers. PLoS One. 2012; 7: 38428.
118. Smith BA, Smith BD. Biomarkers and molecular probes for cell death imaging and targeted therapeutics. Bioconjug Chem. 2012; 23: 1989-2006.
119. Zeng W, Yao M, Townsend D, Kabalka G, Wall J, Miao W. Biological evaluation of dansylhydrazone derivatives for cancer cell apoptosis imaging. J Nucl Med. 2008; 49(Suppl 1): S351.
120. Zeng W, Yao M, Townsend D, Kabalka G, Wall J, Lepuil M, et al. Synthesis and biological evaluation of (E)-5-(dimethylamino)-N'-(4-fluoro-benzylidene)-naphthalene-1-sulfonohydra zide [DFNSH] as an agent for imaging apoptosis. J Nucl Med. 2008; 49(Suppl 1): S294.
121. Zeng W, Yao ML, Townsend D, Kabalka G, Wall J, Le Puil M, et al. Synthesis, biological evaluation and radiochemical labeling of a dansylhydrazone derivative as a potential imaging agent for apoptosis. Bioorg Med Chem Lett. 2008; 18: 3573-7.
122. Zeng W, Miao W, Le Puil M, Shi G, Biggerstaff J, Kabalka GW, et al. Design, synthesis, and biological evaluation of 4-(5-dimethylamino-naphthalene-1-sulfon-amido)-3-(4-iodophenyl)butanoic acid as a novel molecular probe for apoptosis imaging. Biochem Biophys Res Commun. 2010; 398: 571-5.
123. Lee D, Long SA, Murray JH, Adams JL, Nuttall ME, Nadeau DP, et al. Potent and selective nonpeptide inhibitors of caspases 3 and 7. J Med Chem. 2001; 44:2015-26.
124. Chu W, Zhang J, Zeng C, Rothfuss J, Tu Z, Chu Y, et al. N-benzylisatin sulfonamide analogues as potent caspase-3 inhibitors: synthesis, in vitro activity, and molecular modeling studies. J Med Chem. 2005; 48: 7637-47.
125. Kopka K, Faust A, Keul P, Wagner S, Breyholz HJ, Höltke C, et al. 5-pyrrolidinylsulfonyl isatins as a potential tool for the molecular imaging of caspases in apoptosis. J Med Chem. 2006; 49: 6704-15.
126. Zhou D, Chu W, Rothfuss J, Zeng C, Xu J, Jones L, et al. Synthesis, radiolabeling, and in vivo evaluation of an 18F-labeled isatin analog for imaging caspase-3 activation in apoptosis. Bioorg Med Chem Lett. 2006; 16: 5041-6.
127. Barthel H, Cleij MC, Collingridge DR, Hutchinson OC, Osman S, He Q, et al. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res. 2003; 63: 3791-8.
128. Leyton J, Latigo JR, Perumal M, Dhaliwal H, He Q, Aboagye EO. Early detection of tumor response to chemotherapy by 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res. 2005; 65: 4202-10.
129. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007; 34: 1339-47.
130. Nguyen QD, Smith G, Glaser M, Perumal M, Arstad E, Aboagye EO. Positron emission tomography imaging of drug-induced tumor apoptosis with a caspase-3/7 specific [18F]-labeled isatin sulfonamide. Proc Natl Acad Sci U S A. 2009; 106: 16375-80.
131. Glaser M, Goggi J, Smith G, Morrison M, Luthra SK, Robins E, et al. Improved radiosynthesis of the apoptosis marker 18F-ICMT11 including biological evaluation. Bioorg Med Chem Lett. 2011; 21: 6945-9.
132. Nguyen QD, Challapalli A, Smith G, Fortt R, Aboagye EO. Imaging apoptosis with positron emission tomography: 'bench to bedside' development of the caspase-3/7 specific radiotracer [18F]ICMT-11. Eur J Cancer. 2012; 48: 432-40.
133. Challapalli A, Kenny LM, Hallett WA, Kozlowski K, Tomasi G, Gudi M, et al. 18F-ICMT-11, a caspase-3-specific PET tracer for apoptosis: biodistribution and radiation dosimetry. J Nucl Med. 2013; 54: 1551-6.
134. Ly JD, Grubb DR, Lawen A. The mitochondrial membrane potential (deltapsi( m)) in apoptosis; an update. Apoptosis. 2003; 8: 115-28.
135. Madar I, Ravert HT, Du Y, Hilton J, Volokh L, Dannals RF, et al. Characterization of uptake of the new PET imaging compound 18F-fluorobenzyl triphenyl phosphonium in dog myocardium. J Nucl Med. 2006; 47: 1359-66.
136. Madar I, Ravert H, Nelkin B, Abro M, Pomper M, Dannals R, et al. Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation. Eur J Nucl Med Mol Imaging. 2007; 34: 2057-65.
137. Madar I, Huang Y, Ravert H, Dalrymple SL, Davidson NE, Isaacs JT, et al. Detection and quantification of the evolution dynamics of apoptosis using the PET voltage sensor 18F-fluorobenzyl triphenyl phosphonium. J Nucl Med. 2009; 50: 774-80.
138. Nguyen QD, Aboagye EO. Imaging the life and death of tumors in living subjects: Preclinical PET imaging of proliferation and apoptosis. Integr Biol. 2010; 2: 483-95.
139. Rodina A, Vilenchik M, Moulick K, Aguirre J, Kim J, Chiang A, et al. Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer. Nat Chem Biol. 2007;3: 498-507.
140. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res. 2009; 15: 9-14.
141. Park D, Don AS, Massamiri T, Karwa A, Warner B, MacDonald J, et al. Noninvasive imaging of cell death using an Hsp90 ligand. J Am Chem Soc. 2011; 133: 2832-5.
142. Kumar S, Richards-Kortum R. Optical molecular imaging agents for cancer diagnostics and therapeutics. Nanomedicine. 2006; 1: 23-30.
143. Achilefu S. The insatiable quest for near-infrared fluorescent probes for molecular imaging. Angew Chem Int Ed. 2010; 49: 9816-8.
144. Li C, Lee CJ, Simeone DM. Identification of human pancreatic cancer stem cells. Methods Mol Biol. 2009; 568: 161-73.
145. Xia Z, Rao J. Biosensing and imaging based on bioluminescence resonance energy transfer. Curr. Opin Biotechnol. 2009; 20: 37-44.
146. Petrovsky A, Schellenberger E, Josephson L, Weissleder R, Bogdanov A Jr. Near-infrared fluorescent imaging of tumor apoptosis. Cancer Res. 2003; 63:1936-42.
147. Ntziachristos V, Schellenberger EA, Ripoll J, Yessayan D, Graves E, Bogdanov A Jr, et al. Visualization of antitumor treatment by means of fluorescence molecular tomography with an annexin V-Cy5.5 conjugate. Proc Natl Acad Sci U S A. 2004; 101: 12294-9.
148. Smith BA, Akers WJ, Leevy WM, Lampkins AJ, Xiao S, Wolter W, et al. Optical imaging of mammary and prostate tumors in living animals using a synthetic near infrared zinc(II)-dipicolylamine probe for anionic cell surfaces. J Am Chem Soc. 2010; 132: 67-9.
149. Smith BA, Gammon ST, Xiao S, Wang W, Chapman S, McDermott R, et al. In vivo optical imaging of acute cell death using a near-infrared fluorescent zinc-dipicolylamine probe. Mol Pharm. 2011; 8: 583-90.
150. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008; 452: 580-9.
151. Kobayashi H, Choyke PL. Target-cancer-cell-specific activatable fluorescence imaging probes: rational design and in vivo applications. Acc Chem Res. 2011; 44: 83-90.
152. Elias DR, Thorek DL, Chen AK, Czupryna J, Tsourkas A. In vivo imaging of cancer biomarkers using activatable molecular probes. Cancer Biomark. 2008; 4: 287-305.
153. Huang X, Lee S, Chen X. Design of "smart" probes for optical imaging of apoptosis. Am J Nucl Med Mol Imaging. 2007; 1: 3-17.
154. Bullok K, Piwnica-Worms D. Synthesis and characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. J Med Chem. 2005; 48: 5404-7.
155. Bullok KE, Maxwell D, Kesarwala AH, Gammon S, Prior JL, Snow M, et al. Biochemical and in vivo characterization of a small, membrane-permeant, caspase-activatable far-red fluorescent peptide for imaging apoptosis. Biochemistry. 2007; 46: 4055-65.
156. Barnett EM, Zhang X, Maxwell D, Chang Q, Piwnica-Worms D. Single-cell imaging of retinal ganglion cell apoptosis with a cell-penetrating, activatable peptide probe in an in vivo glaucoma model. Proc Natl Acad Sci U S A. 2009; 106: 9391-6.
157. Maxwell D, Chang Q, Zhang X, Barnett EM, Piwnica-Worms D. An improved cell-penetrating, caspase-activatable, near-infrared fluorescent peptide for apoptosis imaging. Bioconjug Chem. 2009; 20: 702-9.
158. Lee S, Choi KY, Chung H, Ryu JH, Lee A, Koo H, et al. Real time, high resolution video imaging of apoptosis in single cells with a polymeric nanoprobe. Bioconjug Chem. 2011; 22: 125-31.
159. Zhu L, Huang X, Choi KY, Ma Y, Zhang F, Liu G, et al. Real-time monitoring of caspase cascade activation in living cells. J Control Release. 2012; 163: 55-62.
160. Huang X, Swierczewska M, Choi KY, Zhu L, Bhirde A, Kim K, et al. Multiplex imaging of an intracellular proteolytic cascade by using a broad-spectrum nanoquencher. Angew Chem Int Ed. 2012; 51: 1625-30.
161. Troy T, Jekic-McMullen D, Sambucetti L, Rice B. Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models. Mol Imaging. 2004; 3: 9-23.
162. Ponomarev V, Doubrovin M, Serganova I, Vider J, Shavrin A, Beresten T, et al. A novel triple-modality reporter gene for whole-body fluorescent, bioluminescent, and nuclear noninvasive imaging. Eur J Nucl Med Mol Imaging. 2004; 31: 740-51.
163. Kanno A, Yamanaka Y, Hirano H, Umezawa Y, Ozawa T. Cyclic luciferase for real-time sensing of caspase-3 activities in living mammals. Angew Chem Int Ed. 2007; 46: 7595-9.
164. Zhang F, Zhu L, Liu G, Hida N, Lu G, Eden HS, et al. Multimodality imaging of tumor response to doxil. Theranostics. 2011; 1: 302-9.
165. Niu G, Zhu L, Ho DN, Zhang F, Quan Q, Hida N, et al. Longitudinal bioluminescence imaging of the dynamics of Doxorubicin induced apoptosis. Theranostics. 2013; 3: 190-200.
166. Bhaumik S, Gambhir SS. Optical imaging of Renilla luciferase reporter gene expression in living mice. Proc Natl Acad Sci U S A. 2002; 99: 377-82.
167. Shah K, Tang Y, Breakefield X, Weissleder R. Real-time imaging of TRAIL-induced apoptosis of glioma tumors in vivo. Oncogene. 2003; 22:6865-72.
168. Angers S, Salahpour A, Joly E, Hilairet S, Chelsky D, Dennis M, et al. Detection of beta 2-adrenergic receptor dimerization in living cells using bioluminescence resonance energy transfer (BRET). Proc Natl Acad Sci U S A. 2000; 97:3684-9.
169. Blamire AM. The technology of MRI--the next 10 years? Br J Radiol. 2008; 81:601-17.
170. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev. 1999; 99: 2293-352.
171. Lee N, Hyeon T. Designed synthesis of uniformly sized iron oxide nanoparticles for efficient magnetic resonance imaging contrast agents. Chem Soc Rev. 2012; 41: 2575-89.
172. Zhou Z, Lu ZR. Gadolinium-based contrast agents for magnetic resonance cancer imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2013; 5:1-18.
173. Xie J, Liu G, Eden HS, Ai H, Chen X. Surface-engineered magnetic nanoparticle platforms for cancer imaging and therapy. Acc Chem Res. 2011; 44: 883-92.
174. Tan H, Yu L, Gao F, Liao W, Wang W, Zeng W. Surface modification: how nanoparticles assemble to molecular imaging probes. J Nanopart Res. 2013; 15:2100-15.
175. Caravan P. Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. Chem Soc Rev. 2006; 35: 512-23.
176. Hiller KH, Waller C, Nahrendorf M, Bauer WR, Jakob PM. Assessment of cardiovascular apoptosis in the isolated rat heart by magnetic resonance molecular imaging. Mol Imaging. 2006;5: 115-21.
177. van Tilborg GA, Mulder WJ, Deckers N, Storm G, Reutelingsperger CP, Strijkers GJ, et al. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug Chem. 2006; 17: 741-9.
178. van Tilborg GA, Vucic E, Strijkers GJ, Cormode DP, Mani V, Skajaa T, et al. Annexin A5-functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques. Bioconjug Chem. 2011; 21: 1794-803.
179. Krishnan AS, Neves AA, de Backer MM, Hu DE, Davletov B, Kettunen MI, et al. Detection of cell death in tumors by using MR imaging and a gadolinium-based targeted contrast agent. Radiology. 2008; 246: 854-62.
180. Burtea C, Laurent S, Lancelot E, Ballet S, Murariu O, Rousseaux O, et al. Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques. Mol Pharm. 2009; 6: 1903-19.
181. Kikuchi K. Design, synthesis and biological application of chemical probes for bio-imaging. Chem Soc Rev. 2010; 39: 2048-53.
182. Mizukami S, Takikawa R, Sugihara F, Hori Y, Tochio H, Wälchli M, et al. Paramagnetic relaxation-based 19F MRI probe to detect protease activity. J Am Chem Soc. 2008; 130: 794-5.
183. Mizukami S, Takikawa R, Sugihara F, Shirakawa M, Kikuchi K. Dual-function probe to detect protease activity for fluorescence measurement and 19F MRI. Angew Chem Int Ed. 2009; 48: 3641-3.
184. Yoo B, Pagel MD. A PARACEST MRI contrast agent to detect enzyme activity. J Am Chem Soc. 2006; 128: 14032-3.
185. Reddy LH, Arias JL, Nicolas J, Couvreur P. Magnetic nanoparticles: design and characterization, toxicity and biocompatibility, pharmaceutical and biomedical applications. Chem Rev. 2012; 112: 5818-78.
186. Tassa C, Shaw SY, Weissleder R. Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. Acc Chem Res. 2011; 44: 842-52.
187. Schellenberger EA, Bogdanov A, Högemann D, Tait J, Weissleder R, Josephson L. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Mol Imaging. 2002; 1: 102-7.
188. van Tilborg GA, Geelen T, Duimel H, Bomans PH, Frederik PM, Sanders HM, et al. Internalization of annexin A5-functionalized iron oxide particles by apoptotic Jurkat cells. Contrast Media Mol Imaging. 2009; 4: 24-32.
189. Oling F, Santos JS, Govorukhina N, Mazères-Dubut C, Bergsma-Schutter W, Oostergetel G, et al. Structure of membrane-bound annexin A5 trimers: a hybrid cryo-EM - X-ray crystallography study. J Mol Biol. 2000; 304: 561-73.
190. Zhao M, Beauregard DA, Loizou L, Davletov B, Brindle KM. Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent. Nat Med. 2001; 7: 1241-4.
191. Radermacher KA, Boutry S, Laurent S, Elst LV, Mahieu I, Bouzin C, et al. Iron oxide particles covered with hexapeptides targeted at phosphatidylserine as MR biomarkers of tumor cell death. Contr Media Mol Imaging. 2010; 5: 258-67.
192. Radermacher KA, Magat J, Bouzin C, Dresselaers T, Himmelreich U, Boutry S, et al. Multimodal assessment of early tumor response to chemotherapy: comparison between diffusion-weighted MRI,1H-MR spectroscopy of choline and USPIO particles targeted at cell death. NMR Biomed. 2011; 25: 514-22.
193. Burtea C, Ballet S, Laurent S, Rousseaux O, Dencausse A, Gonzalez W, et al. Development of a magnetic resonance imaging protocol for the characterization of atherosclerotic plaque by using vascular cell adhesion molecule-1 and apoptosis-targeted ultrasmall superparamagnetic iron oxide derivatives. Arterioscler Thromb Vasc Biol. 2012; 32: e36-348.
194. Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discovery. 2008; 7: 591-607.
195. Louie A. Multimodality imaging probes: design and challenges. Chem Rev. 2010; 110: 3146-95.
196. Sapsford KE, Algar WR, Berti L, Gemmill KB, Casey BJ, Oh E, et al. Functionalizing nanoparticles with biological molecules: developing chemistries that facilitate nanotechnology. Chem Rev. 2013; 113: 1904-2074.
197. Xing Y, Zhao J, Conti PS, Chen K. Radiolabeled nanoparticles for multimodality tumor imaging. Theranostics. 2014; 4: 290-306.
198. Lee DE, Koo H, Sun IC, Ryu JH, Kim K, Kwon IC. Multifunctional nanoparticles for multimodal imaging and theragnosis. Chem Soc Rev. 2012; 41: 2656-72.
199. Schellenberger EA, Sosnovik D, Weissleder R, Josephson L. Magneto/optical annexin V, a multimodal protein. Bioconjug Chem. 2004; 15: 1062-7.
200. Sosnovik DE, Schellenberger EA, Nahrendorf M, Novikov MS, Matsui T, Dai G, et al. Magnetic resonance imaging of cardiomyocyte apoptosis with a novel magneto-optical nanoparticle. Magn Reson Med. 2005; 54: 718-24.
201. van Tilborg GA, Mulder WJ, Chin PT, Storm G, Reutelingsperger CP, Nicolay K, et al. Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug Chem. 2006; 17: 865-8.
202. van Tilborg GA, Vucic E, Strijkers GJ, Cormode DP, Mani V, Skajaa T, et al. Annexin A5-functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques. Bioconjug Chem. 2010; 21: 1794-803.
203. Zhang R, Lu W, Wen X, Huang M, Zhou M, Liang D, et al. Annexin A5-conjugated polymeric micelles for dual SPECT and optical detection of apoptosis. J Nucl Med. 2011; 52: 958-64.
204. Zhang R, Huang M, Zhou M, Wen X, Huang Q, Li C. Annexin A5-functionalized nanoparticle for multimodal imaging of cell death. Mol Imaging. 2013; 12: 182-90.
205. Zhang L, Zhou H, Belzile O, Thorpe P, Zhao D. Phosphatidylserine-targeted bimodal liposomal nanoparticles for in vivo imaging of breast cancer in mice. J Control Release. 2014; 183: 114-23.
206. Lee H, Akers WJ, Cheney PP, Edwards WB, Liang K, Culver JP, et al. Complementary optical and nuclear imaging of caspase-3 activity using combined activatable and radio-labeled multimodality molecular probe. J Biomed Opt. 2009; 14: 040507.
207. Blankenberg, FG. In vivo detection of apoptosis. J Nucl Med. 2008; 49(Suppl 2):S81-S95.
208. Reshef A, Shirvan A, Akselrod-Ballin A, Wall A, and Ziv I. Small-molecule biomarkers for clinical PET imaging of apoptosis. J Nucl Med. 2010; 51: 837-40.
209. Niu G, Chen X. Apoptosis imaging: beyond annexin V. J Nucl Med. 2010; 51:1659-62.
210. Vangestel C, Peeters M, Mees G, Oltenfreiter R, Boersma HH, Elsinga PH, et al. In vivo imaging of apoptosis in oncology: an update. Mol Imaging. 2011; 10:340-58.
211. Neves AA, Brindle KM. Focus on molecular imaging. J Nucl Med. 2014; 55:1-4.
212. Chen K, Chen X. Design and development of molecular imaging probes. Curr Top Med Chem. 2010; 10: 1227-36.
213. Skovronsky D. Use of eINDs for evaluation of multiple related PET amyloid plaque imaging agents. J Nucl Med. 2008; 49: 4-8.
214. Chi C, Du Y, Ye J, Kou D, Qiu J, Wang J, et al. Intraoperative imaging-guided cancer surgery: from current fluorescence molecular imaging methods to future multi-modality imaging technology. Theranostics. 2014; 4: 1072-84.
215. Shirvan A. Apoptosis imaging with PET-18F-ML-10 for early assessment of response of brain metastasis to radiotherapy. J Nucl Med. 2009; 50(Suppl 1):S118.
216. Martinez MM, Reif RD, Pappas D. Detection of apoptosis: a review of conventional and novel techniques. Anal Methods. 2010; 2: 996-1004.
217. Jokerst JV, Gambhir SS. Molecular imaging with theranostic nanoparticles. Acc Chem Res. 2011; 44: 1050-60.
218. Lammers T, Aime S, Hennink WE, Storm G, Kiessling F. Theranostic nanomedicine. Acc Chem Res. 2011; 44: 1029-38.
219. Chen X, Gambhir SS, Cheon J. Theranostic nanomedicine. Acc Chem Res. 2011; 44: 841.
220. Xie J, Jon S. Magnetic nanoparticle-based theranostics. Theranostics. 2012; 2:122-4.
221. Muthu MS, Leong DT, Mei L, Feng SS. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics. 2014; 4: 660-77.
222. Lee S, Kim K. Protease activity: meeting its theranostic potential. Theranostics. 2012; 2: 125-6.
223. Min Y, Li J, Liu F, Yeow EK, Xing B. Near-infrared light-mediated photoactivation of a platinum antitumor prodrug and simultaneous cellular apoptosis imaging by upconversion-luminescent nanoparticles. Angew Chem Int Ed. 2014; 53: 1012-6.